Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China

American Journal on Addictions

Volumn 23, Issue 3, 2014, Pages 313-317

  Sun, Hong Qiang ^a,b   Chen, Hong Mei ^b   Yang, Fu De ^b   Lu, Lin ^b   Kosten, Thomas R ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE TYPE STIMULANT; CENTRAL STIMULANT AGENT; FLUOXETINE; MORPHINE; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ACUPUNCTURE; AMPHETAMINE TYPE STIMULANT DEPENDENCE; CANNABIS ADDICTION; CHINA; CHINESE MEDICINE; DEPRESSION; DRUG DEPENDENCE; DRUG INTOXICATION; HUMAN; MORPHINE ADDICTION; NONHUMAN; REVIEW; TRADITIONAL MEDICINE; WITHDRAWAL SYNDROME; ANIMAL; DRUG ABUSE; DRUG COMBINATION; DRUG THERAPY; EPIDEMIOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; THERAPY;

ACUPUNCTURE THERAPY; AMPHETAMINE-RELATED DISORDERS; ANIMALS; CHINA; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FLUOXETINE; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84898922362     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2014.12116.x     Document Type: Review

References (51)

1. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008; 33: 1162-1170.
2. Bao YP, Liu ZM., Currents situation and trends of drug abuse and HIV/AIDS in China. HIV Therapy. 2009; 3: 237-240.
3. Zhang Y, Lu C, Zhang J, et al. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China. Addict Behav. 2013; 38: 1424-1430.
4. Cao XB, Wu ZY, Pang L, et al. Evaluation on the long-term effectiveness among the first set eight methadone maintenance treatment clinics in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2012; 33: 879-882.
5. Fang YX, Wang YB, Shi J, et al. Recent trends in drug abuse in China. Acta Pharmacol Sin. 2006; 27: 140-144.
6. Lu L, Wang X., Drug addiction in China. Ann N Y Acad Sci. 2008; 1141: 304-317.
7. World Drug Report 2010. United Nations Office on Drugs and Crime; 2010. http://www.unodc.org/unodc/data-and-analysis/WDR-2010.html
8. SFDA. State Food and Drug Administration of the People's Republic of China; 2011. http://www.sfda.gov.cn/WS01/CL0051/73928.html
9. CNCBMPS. 2011. http://www.mps.gov.cn/n16/n80209/n80481/n804535/2804926. html
10. CNCBMPS. 2005. http://www.mps.gov.cn/n16/n80209/n80481/n804535/804651. html
11. APA. Diagnositic and Statistic Manual of Mental Disorder, 4th edn, text revision. Washington, DC: American Psychiatric Association; 2000
12. CMH. 2009. http://www.moh.gov.cn/mohbgt/s10695/200912/45283.shtml
13. Shi J, Xu GZ, Liu TT, et al. A comparative clinical study of the effects of the traditional Chinese medicine Jinniu capsules and lofexidine on acute heroin withdrawal symptoms. Am J Drug Alcohol Abuse. 2008; 34: 792-800.
14. Jordan JB, Tu X., Advances in heroin addiction treatment with traditional Chinese medicine: A systematic review of recent Chinese language journals. Am J Chin Med. 2008; 36: 437-447.
15. Wu JM, Wei DY, Luo YF, et al. Clinic research on heroin de-addiction effects of acupuncture and its potentiality of preventing relapse. Zhong Xi Yi Jie He Xue Bao. 2003; 1: 268-272.
16. Cui CL, Wu LZ, Luo F., Acupuncture for the treatment of drug addiction. Neurochem Res. 2008; 33: 2013-2022.
17. Ulett GA, Han S, Han JS., Electroacupuncture: Mechanisms and clinical application. Biol Psychiatry. 1998; 44: 129-138.
18. Lu L, Liu Y, Zhu W, et al. Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse. 2009; 35: 1-11.
19. Leelahanaj T, Kongsakon R, Netrakom P., A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai Chotmaihet Thangphaet. 2005; 88: S43-S52.
20. Jha A, Fourie H., Risperidone treatment of amphetamine psychosis. Br J Psychiatry. 1999; 174: 366.
21. Misra L, Kofoed L., Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997; 154: 1170.
22. Meredith CW, Jaffe C, Yanasak E, et al. An open-label pilot study of risperidone in the treatment of methamphetamine dependence. J Psychoactive Drugs. 2007; 39: 167-172.
23. Misra LK, Kofoed L, Oesterheld JR, et al. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol. 2000; 20: 393-394.
24. Pan YF, Wang YD, Zhou H., Sheng Mai Injection in the treatment of ecstasy poisoning arrhythmia in 10 cases. Henan Tradit Chin Med. 2006; 7: 68-69.
25. Wang HC, Dou YF., The effect of Xing Nao Jing Injection combined with naloxone in treatment of acute intoxication of MDMA. Clin Misdiagnosis Mistherapy. 2011; 24: 118-119.
26. Xia EZ, Zhang Y, Wang P, et al. Jia Wei Xiao Yao Powder combined with fluoxetine in the treatment of amphetamine-type stimulants abuser with depressive symptoms in 30 cases. J Tradit Chin Med. 2011; 52: 1507-1508.
27. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008; 96: 222-232.
28. Brensilver M, Heinzerling KG, Swanson AN, et al. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend. 2012; 125: 169-172.
29. Jayaram-Lindstrom N, Wennberg P, Hurd YL, et al. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol. 2004; 24: 665-669.
30. Jayaram-Lindstrom N, Konstenius M, Eksborg S, et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology. 2008; 33: 1856-1863.
31. Jayaram-Lindstrom N, Hammarberg A, Beck O, et al. Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial. Am J Psychiatry. 2008; 165: 1442-1448.
32. Hiranita T, Nawata Y, Sakimura K, et al. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci USA. 2006; 103: 8523-8527.
33. De La Garza R II, Newton TF, Haile CN, et al. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 37: 141-146.
34. De La Garza R II, Mahoney JJ III, Culbertson C, et al. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav. 2008; 89: 200-208.
35. Attele AS, Wu JA, Yuan CS., Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol. 1999; 58: 1685-1693.
36. Takahashi M, Tokuyama S., Pharmacological and physiological effects of ginseng on actions induced by opioids and psychostimulants. Methods Find Exp Clin Pharmacol. 1998; 20: 77-84.
37. Kim HS, Jang CG, Park WK, et al. Blockade by ginseng total saponin of methamphetamine-induced hyperactivity and conditioned place preference in mice. Gen Pharmacol. 1996; 27: 199-204.
38. Wu CF, Liu YL, Song M, et al. Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice. Pharmacol Biochem Behav. 2003; 76: 103-109.
39. Sershen H, Harsing LG Jr, Hashim A, et al. Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats. Life Sci. 1992; 51: 1003-1011.
40. Yu X, Imam SZ, Newport GD, et al. Ibogaine blocked methamphetamine- induced hyperthermia and induction of heat shock protein in mice. Brain Res. 1999; 823: 213-216.
41. Thongsaard W, Marsden CA., A herbal medicine used in the treatment of addiction mimics the action of amphetamine on in vitro rat striatal dopamine release. Neurosci Lett. 2002; 329: 129-132.
42. Thongsaard W, Marsden CA, Morris P, et al. Effect of Thunbergia laurifolia, a Thai natural product used to treat drug addiction, on cerebral activity detected by functional magnetic resonance imaging in the rat. Psychopharmacology. 2005; 180: 752-760.
43. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996; 184: 86-94.
44. Lee NK, Rawson RA., A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008; 27: 309-317.
45. Roll JM, Petry NM, Stitzer ML, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006; 163: 1993-1999.
46. Menza TW, Jameson DR, Hughes JP, et al. Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: A randomized controlled trial. BMC Public Health. 2010; 10: 774.
47. Kosten TR, Newton TF, De La Garza R II, et al. Cocaine and Methamphetamine Dependence: Advances in Treatment. Arlington, VA: American Psychiatric Publishing; 2011.
48. Baker A, Bucci S, Lewin TJ, et al. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry. 2006; 188: 439-448.
49. Bowler JO, Mackintosh B, Dunn BD, et al. A comparison of cognitive bias modification for interpretation and computerized cognitive behavior therapy: Effects on anxiety, depression, attentional control, and interpretive bias. J Consult Clin Psychol. 2012; 80: 1021-1033.
50. Donovan DM, Wells EA., " Tweaking 12-Step": The potential role of 12-Step self-help group involvement in methamphetamine recovery. Addiction. 2007; 102: 121-129.
51. Cai Y, Wang X, Jiang LJ., The effect of electroacupuncture on the somatic symptoms induced by using psychoactive substances. Chin J Drug Depend. 2012; 21: 159-160.